UnitedHealth Group (UNH) – Investment Analysts’ Recent Ratings Updates

UnitedHealth Group (NYSE: UNH) has recently received a number of price target changes and ratings updates:

  • 12/2/2019 – UnitedHealth Group had its price target raised by analysts at Barclays PLC from $260.00 to $305.00. They now have an “overweight” rating on the stock.
  • 11/26/2019 – UnitedHealth Group had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $300.00 price target on the stock, up previously from $270.00.
  • 11/22/2019 – UnitedHealth Group had its “buy” rating reaffirmed by analysts at Morgan Stanley. They now have a $312.00 price target on the stock, up previously from $294.00.
  • 11/18/2019 – UnitedHealth Group had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $335.00 price target on the stock, up previously from $310.00.
  • 10/17/2019 – UnitedHealth Group had its price target lowered by analysts at UBS Group AG from $281.00 to $257.00. They now have a “neutral” rating on the stock.
  • 10/17/2019 – UnitedHealth Group is now covered by analysts at Mizuho. They set a “buy” rating and a $270.00 price target on the stock.
  • 10/16/2019 – UnitedHealth Group had its price target lowered by analysts at Citigroup Inc from $299.00 to $286.00. They now have a “buy” rating on the stock.
  • 10/15/2019 – UnitedHealth Group was given a new $310.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/10/2019 – UnitedHealth Group was downgraded by analysts at Jefferies Financial Group Inc from a “buy” rating to a “hold” rating. They now have a $235.00 price target on the stock, down previously from $300.00.
  • 10/8/2019 – UnitedHealth Group was given a new $310.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/8/2019 – UnitedHealth Group was given a new $260.00 price target on by analysts at Barclays PLC. They now have a “buy” rating on the stock.

UNH opened at $277.87 on Tuesday. The firm has a market capitalization of $265.15 billion, a P/E ratio of 21.57, a P/E/G ratio of 1.48 and a beta of 0.64. The firm’s 50 day moving average is $258.05 and its 200-day moving average is $245.34. UnitedHealth Group Inc has a 52-week low of $208.07 and a 52-week high of $287.94. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 0.67.

UnitedHealth Group (NYSE:UNH) last announced its earnings results on Tuesday, October 15th. The healthcare conglomerate reported $3.88 earnings per share for the quarter, beating the consensus estimate of $3.75 by $0.13. The business had revenue of $60.35 billion during the quarter, compared to the consensus estimate of $59.84 billion. UnitedHealth Group had a net margin of 5.57% and a return on equity of 25.30%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.41 earnings per share. Equities analysts expect that UnitedHealth Group Inc will post 14.96 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 17th. Shareholders of record on Monday, December 9th will be given a $1.08 dividend. The ex-dividend date is Friday, December 6th. This represents a $4.32 dividend on an annualized basis and a yield of 1.55%. UnitedHealth Group’s payout ratio is currently 33.54%.

In other UnitedHealth Group news, Director Richard T. Burke sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $232.76, for a total value of $581,900.00. Following the transaction, the director now directly owns 187,979 shares of the company’s stock, valued at approximately $43,753,992.04. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Thomas E. Roos sold 1,177 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $255.04, for a total value of $300,182.08. Following the completion of the transaction, the chief accounting officer now directly owns 21,687 shares in the company, valued at $5,531,052.48. The disclosure for this sale can be found here. Insiders have sold 38,577 shares of company stock valued at $9,398,080 over the last 90 days. Insiders own 0.82% of the company’s stock.

Several large investors have recently modified their holdings of the stock. Nuveen Asset Management LLC lifted its position in shares of UnitedHealth Group by 1,354.6% during the second quarter. Nuveen Asset Management LLC now owns 8,540,562 shares of the healthcare conglomerate’s stock worth $2,083,983,000 after purchasing an additional 7,953,416 shares during the last quarter. Boston Partners increased its stake in UnitedHealth Group by 160.8% during the second quarter. Boston Partners now owns 2,550,998 shares of the healthcare conglomerate’s stock valued at $622,942,000 after purchasing an additional 1,572,711 shares during the last quarter. Viking Global Investors LP raised its holdings in shares of UnitedHealth Group by 28.6% during the second quarter. Viking Global Investors LP now owns 4,812,185 shares of the healthcare conglomerate’s stock worth $1,174,221,000 after purchasing an additional 1,071,149 shares during the period. Janus Henderson Group PLC raised its holdings in shares of UnitedHealth Group by 16.7% during the second quarter. Janus Henderson Group PLC now owns 6,448,289 shares of the healthcare conglomerate’s stock worth $1,573,438,000 after purchasing an additional 922,290 shares during the period. Finally, Barrow Hanley Mewhinney & Strauss LLC raised its holdings in shares of UnitedHealth Group by 63.3% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 1,705,888 shares of the healthcare conglomerate’s stock worth $416,254,000 after purchasing an additional 661,064 shares during the period. Institutional investors and hedge funds own 85.50% of the company’s stock.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

Further Reading: Analyst Ratings Trading

Receive News & Ratings for UnitedHealth Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.